Magenta Therapeutics, a biotechnology company, agreed to merge with Dianthus Therapeutics, a clinical-stage biotechnology. Financial terms were not disclosed. “After a thorough exploration of our strategic alternatives, management and our Board of Directors believe the transaction with Dianthus Therapeutics will culminate in a successful outcome for our stockholders. Dianthus has made rapid progress in developing and advancing DNTH103 into the clinic where it has the potential to be a transformative classical pathway inhibitor for severe autoimmune diseases. We are extremely grateful to our current and former employees who contributed to Magenta’s efforts to develop its programs and we now look forward to the combined company’s advancement on opportunities for value creation for patients,” Steve Mahoney, Magenta President and Chief Financial and Operating Officer.